Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent W Mouw

Showing results (21-30 of 121) with videos related to

Pageof 13
Sort By:
Molecular Microbiology|June 11, 2009
Regulatory mutations in Sin recombinase support a structure-based model of the synaptosomeSally-J Rowland, Martin R Boocock, Arlene L McPherson, et al.
The Journal of Biological Chemistry|August 24, 2013
Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavageRoss A Keenholtz, Kent W Mouw, Martin R Boocock, et al.
Molecular Cell|April 29, 2008
Architecture of a serine recombinase-DNA regulatory complexKent W Mouw, Sally-J Rowland, Mark M Gajjar, et al.
Biochemical Society Transactions|March 20, 2010
Orchestrating serine resolvasesPhoebe A Rice, Kent W Mouw, Sherwin P Montaño, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancerSurish P Shanmugam, Yuzhen Zhou, Isabella Stelter, et al.
The Prostate|June 2, 2022
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapyHae Lin Cho, Vedang Murthy, Kent W Mouw, et al.
NPJ Precision Oncology|June 29, 2022
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancerKasia M Dillon, Raie T Bekele, Zsofia Sztupinszki, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataOlivera Stojkova, Judit Börcsök, Zsofia Sztupinszki, et al.
Cancer Research|January 31, 2015
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistanceRaphael Ceccaldi, Kevin W O'Connor, Kent W Mouw, et al.
Cancer|June 1, 2019
Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancerSantino S Butler, Brandon A Mahal, Nayan Lamba, et al.
Pageof 13

Showing results (21-30 of 121) with videos related to

Sort By:
Pageof 13
Molecular Microbiology|June 11, 2009
Regulatory mutations in Sin recombinase support a structure-based model of the synaptosomeSally-J Rowland, Martin R Boocock, Arlene L McPherson, et al.
The Journal of Biological Chemistry|August 24, 2013
Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavageRoss A Keenholtz, Kent W Mouw, Martin R Boocock, et al.
Molecular Cell|April 29, 2008
Architecture of a serine recombinase-DNA regulatory complexKent W Mouw, Sally-J Rowland, Mark M Gajjar, et al.
Biochemical Society Transactions|March 20, 2010
Orchestrating serine resolvasesPhoebe A Rice, Kent W Mouw, Sherwin P Montaño, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancerSurish P Shanmugam, Yuzhen Zhou, Isabella Stelter, et al.
The Prostate|June 2, 2022
Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapyHae Lin Cho, Vedang Murthy, Kent W Mouw, et al.
NPJ Precision Oncology|June 29, 2022
PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancerKasia M Dillon, Raie T Bekele, Zsofia Sztupinszki, et al.
Biorxiv : the Preprint Server for Biology|February 27, 2026
Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataOlivera Stojkova, Judit Börcsök, Zsofia Sztupinszki, et al.
Cancer Research|January 31, 2015
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistanceRaphael Ceccaldi, Kevin W O'Connor, Kent W Mouw, et al.
Cancer|June 1, 2019
Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancerSantino S Butler, Brandon A Mahal, Nayan Lamba, et al.
Pageof 13